Gracell Biotechnologies Inc (GRCL) Return on Equity ROE from the fourth quarter 2022 to fourth quarter 2021 and annually, average high and low, overall ranking from Dec 31 2022 to Dec 31 2021 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Gracell Biotechnologies Inc   (NASDAQ: GRCL)

Gracell Biotechnologies Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Gracell Biotechnologies Inc in the fourth quarter 2022?
Gracell Biotechnologies Inc recorded a cumulative net loss of $-88 million during 12 months ending in the fourth quarter 2022, resulting in a negative return on equity (ROE) of -44.23%.

Within the Major Pharmaceutical Preparations industry 220 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2022 from 0 to 3831.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2022)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Equity Change -21.41 % -30.44 % -30.44 % -15.98 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -88 -71 -71 -71 -71
Return On Equity (TTM) -44.23 % -33.78 % -30.6 % -27.97 % -26.76 %
GRCL's Total Ranking # 3831 # 0 # 0 # 0 # 0
Equity (TTM) in Millions 157 199 199 241 199
Seq. Equity Change -21.41 % 0 % -17.21 % 20.79 % -30.44 %
Seq. Net Income Change - - - - -

Back to GRCL Management Effectiveness >> GRCL's 5 Years Annual ROE >> Compare GRCL ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 221
Sector # 500
Overall # 3831

Return On Equity Statistics
High Average Low
-24.72 %
-34.44 %
-44.16 %
(Dec 31 2021)   (Dec 31 2022)





GRCL Annual Return On Equity (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020

Total Equity in Millions 199 287 -90 0 0
Y / Y Equity Change -30.44 % - - - -
Net Income in Millions -88 -71 -32 0 0
Y / Y Net Income Change - - - - -
Return On Equity -44.16 % -24.72 % - - -

Back to GRCL Management Effectiveness >> GRCL's 5 Years Annual ROE >> Compare GRCL ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
GRCL's' Return on Equity at Yahoo Finance
GRCL's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for GRCL's Competitors
Subscribers only: Roe for Gracell Biotechnologies Inc 's Suppliers
Subscribers only: Return On Equity for GRCL's Customers




Companies with similar Return On Equity at Dec 31 2022, within Healthcare Sector ROE

Date modified: 2026-09-08T15:10:54+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.